A quick guide to the most important AI law you’ve never heard of
By Melissa Heikkilä,
MIT Technology Review
| 05. 13. 2022
It’s a Wild West out there for artificial intelligence. AI applications are increasingly used to make important decisions about humans’ lives with little to no oversight or accountability. This can have devastating consequences: wrongful arrests, incorrect grades for students, and even financial ruin. Women, marginalized groups, and people of color often bear the brunt of AI’s propensity for error and overreach.
The European Union thinks it has a solution: the mother of all AI laws, called the AI Act. It is the first law that aims to curb these harms by regulating the whole sector. If the EU succeeds, it could set a new global standard for AI oversight around the world.
But the world of EU legislation can be complicated and opaque. Here’s a quick guide to everything you need to know about the EU’s AI Act. The bill is currently being amended by members of the European Parliament and EU countries.
What’s the big deal?
The AI Act is hugely ambitious. It would require extra checks for “high risk” uses of AI that have the most...
Related Articles
By Rob Stein, NPR | 04.23.2026
The Food and Drug Administration approved the first gene therapy to restore hearing for people who were born deaf.
The decision, while only immediately affecting people born with a very rare form of genetic deafness, is being hailed as...
By Alfonso Martinez Arias, Nicolas Rivron, and Naomi Moris, BioNews | 04.20.2026
By George Janes, BioNews | 04.20.2026
New regulations in sperm donation are being implemented by Belgium's Federal Agency for Medicines and Health Products (FAMHP), following revelations regarding the use of sperm carrying a cancer-causing mutation, and widespread breaches of donor limits.
In 2025, it...
By Sriparna Roy, Reuters | 04.23.2026
The U.S. Food and Drug Administration has approved Regeneron’s gene therapy for a rare genetic form of deafness, the company said on Thursday.
This approval, granted under the FDA’s new priority voucher program, marks the introduction of the first gene...